KIAA1826_8430410K20Rik Activators
KIAA1826 Activators encompass a variety of chemical compounds that indirectly amplify the functional activity of KIAA1826 through distinct signaling pathways. Forskolin and Isoproterenol elevate cAMP levels, activating PKA, which may phosphorylate KIAA1826, thus enhancing its functional activity. Similarly, Epinephrine, by binding to adrenergic receptors, and IBMX, by inhibiting phosphodiesterases, both lead to increased cAMP levels and subsequent PKA activation, potentially resulting in the phosphorylation and enhanced activity of KIAA1826. The stable cAMP analogs 8-Bromo-cAMP and Dibutyryl-cAMP (db-cAMP) also activate PKA, suggesting a similar enhancement of KIAA1826 activity through phosphorylation. Additionally,BAY 60-7550, by selectively inhibiting PDE2, raises cAMP and cGMP levels, thereby activating PKA or PKG, which could also lead to the phosphorylation and increased activity of KIAA1826.
Calcium signaling is another crucial modulator of KIAA1826's activity, with Ionomycin and A23187 (Calcimycin) both serving as calcium ionophores that raise intracellular calcium levels. This spike in calcium may activate calcium-dependent protein kinases that could phosphorylate KIAA1826, resulting in an enhancement of its activity. Phorbol 12-myristate 13-acetate (PMA) activates PKC, which could then phosphorylate KIAA1826 or associated proteins, further enhancing the protein's activity. S-Nitroso-N-acetylpenicillamine (SNAP) releases nitric oxide, which activates soluble guanylate cyclase, increasing cGMP levels, and the subsequent activation of cGMP-dependent protein kinases may enhance KIAA1826 activity through phosphorylation. Anisomycin, while inhibiting protein synthesis, also activates stress-activated protein kinases (SAPKs), which could lead to enhanced KIAA1826 activity via phosphorylation. Collectively, these activators, through their targeted effects on cellular signaling pathways such as cAMP/PKA, calcium-dependent kinases, PKC, and SAPKs, converge to potentiate the functional activity of KIAA1826 without directly influencing its expression or acting as direct ligands.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels. The increase in calcium can activate calcium-dependent protein kinases, which may phosphorylate KIAA1826, thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates Protein Kinase C (PKC), which can lead to the phosphorylation of KIAA1826 or its associated proteins, thus enhancing KIAA1826's activity through protein-protein interactions or localization changes. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels in cells by stimulating adrenergic receptors. The subsequent activation of PKA can lead to the enhanced activity of KIAA1826 through phosphorylation. | ||||||
Spectinomycin dihydrochloride pentahydrate | 22189-32-8 | sc-203279 sc-203279A | 5 g 10 g | $84.00 $122.00 | 9 | |
SNAP releases nitric oxide (NO), which can activate soluble guanylate cyclase and increase levels of cyclic GMP (cGMP). cGMP-dependent protein kinases may then phosphorylate KIAA1826, enhancing its functional activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA-mediated phosphorylation of KIAA1826 or its regulatory proteins can enhance KIAA1826's activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, leading to increased cAMP and activation of PKA. PKA can then phosphorylate KIAA1826, enhancing its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways which could lead to the phosphorylation and activation of KIAA1826. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which increases intracellular cAMP by preventing its breakdown. Elevated cAMP activates PKA, potentially enhancing the activity of KIAA1826 through phosphorylation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs). Activation of SAPKs can lead to the phosphorylation of KIAA1826, enhancing its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a stable cAMP analog that activates PKA. Through PKA activation, KIAA1826 could be phosphorylated and thus have its activity enhanced. | ||||||